Theriva Biologics Inc (TOVX)
1.28
0.00 (0.00%)
USD |
NYAM |
Nov 22, 16:00
1.29
+0.01
(+0.78%)
After-Hours: 20:00
Theriva Biologics Cash from Financing (Quarterly): 3.716M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.716M |
| June 30, 2024 | 1.773M |
| March 31, 2024 | 0.00 |
| December 31, 2023 | -1.457M |
| September 30, 2023 | 0.001M |
| June 30, 2023 | 2.136M |
| March 31, 2023 | -0.055M |
| December 31, 2022 | -3.288M |
| September 30, 2022 | 2.734M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | -1.376M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 74.00M |
| December 31, 2020 | 3.359M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 22.67M |
| September 30, 2018 | 6.022M |
| Date | Value |
|---|---|
| June 30, 2018 | 0.40M |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.001M |
| September 30, 2017 | 12.40M |
| June 30, 2017 | 5.645M |
| March 31, 2017 | 0.435M |
| December 31, 2016 | 25.26M |
| September 30, 2016 | 0.637M |
| June 30, 2016 | 0.81M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.026M |
| September 30, 2015 | 42.66M |
| June 30, 2015 | 0.001M |
| March 31, 2015 | |
| December 31, 2014 | 19.02M |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.004M |
| December 31, 2013 | 12.20M |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 0.00 |
| March 31, 2013 | 0.231M |
| December 31, 2012 | 10.15M |
| September 30, 2012 | 0.094M |
| June 30, 2012 | 0.416M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-3.288M
Minimum
Dec 2022
74.00M
Maximum
Mar 2021
4.077M
Average
--
Median
Dec 2019
Cash from Financing (Quarterly) Benchmarks
| Merck & Co Inc | -2.425B |
| Pro-Dex Inc | -1.006M |
| BioCardia Inc | 6.122M |
| NovaBay Pharmaceuticals Inc | 2.089M |
| Palatin Technologies Inc | -0.127M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.913M |
| Free Cash Flow | -18.84M |
| Free Cash Flow Per Share (Quarterly) | -3.449 |
| Free Cash Flow Yield | -1.80K% |